Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

被引：0
|
作者：
Myers, Andrea P.
Filiaci, Virginia L.
Zhang, Yuping
Pearl, Michael
Behbakht, Kian
Makker, Vicky
Hanjani, Parviz
Zweizig, Susan
Burke, James J.
Downey, Gordon
Leslie, Kimberly K.
Birrer, Michael J.
Fleming, Gini F.
机构：
[1] Novartis Inst Biomed Res, Cambridge, MA USA
[2] NRG Oncol, Buffalo, NY USA
[3] GOG Fdn Inc SDMC, Buffalo, NY USA
[4] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[5] Univ Hosp Stony Brook, New York, NY USA
[6] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Weill Cornell Med Coll, New York, NY USA
[9] Abington Memor Hosp, Gladwyne, PA USA
[10] Univ Massachusetts Memor Hlth Care, Worcester, MA USA
[11] Mercer Univ, Sch Med, Savannah, GA USA
[12] Gynecol Oncol West Michigan, Grand Rapids, MI USA
[13] Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA
[14] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.5592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5592
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PHASE-II EVALUATION OF DIANHYDROGALACTITOL IN THE TREATMENT OF ADVANCED ENDOMETRIAL ADENOCARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    STEHMAN, FB
    BLESSING, JA
    DELGADO, G
    LOUKA, M
    CANCER TREATMENT REPORTS, 1983, 67 (7-8): : 737 - 738
  • [42] A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study
    Miller, DS
    Blessing, JA
    Lentz, SS
    Waggoner, SE
    GYNECOLOGIC ONCOLOGY, 2002, 87 (03) : 247 - 251
  • [43] A PHASE-II TRIAL OF VINCRISTINE IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    BROUN, GO
    BLESSING, JA
    EDDY, GL
    ADELSON, MD
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (01): : 18 - 21
  • [44] Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
    Behbakht, Kian
    Sill, Michael W.
    Darcy, Kathleen M.
    Rubin, Stephen C.
    Mannel, Robert S.
    Waggoner, Steven
    Schilder, Russell J.
    Cai, Kathy Q.
    Godwin, Andrew K.
    Alpaugh, R. Katherine
    GYNECOLOGIC ONCOLOGY, 2011, 123 (01) : 19 - 26
  • [45] Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
    Karavasilis, Vasilios
    Samantas, Epaminontas
    Koliou, Georgia-Angeliki
    Kalogera-Fountzila, Anna
    Pentheroudakis, George
    Varthalitis, Ioannis
    Linardou, Helena
    Rallis, Grigorios
    Skondra, Maria
    Papadopoulos, Georgios
    Papatsibas, George
    Sgouros, Joseph
    Goudopoulou, Athina
    Kalogeras, Konstantine T.
    Dervenis, Christos
    Pectasides, Dimitrios
    Fountzilas, George
    TARGETED ONCOLOGY, 2018, 13 (06) : 715 - 724
  • [46] Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
    Vasilios Karavasilis
    Epaminontas Samantas
    Georgia-Angeliki Koliou
    Anna Kalogera-Fountzila
    George Pentheroudakis
    Ioannis Varthalitis
    Helena Linardou
    Grigorios Rallis
    Maria Skondra
    Georgios Papadopoulos
    George Papatsibas
    Joseph Sgouros
    Athina Goudopoulou
    Konstantine T. Kalogeras
    Christos Dervenis
    Dimitrios Pectasides
    George Fountzilas
    Targeted Oncology, 2018, 13 : 715 - 724
  • [47] Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study
    Goodfellow, Paul J.
    Billingsley, Caroline C.
    Lankes, Heather A.
    Ali, Shamshad
    Cohn, David E.
    Broaddus, Russell J.
    Ramirez, Nilsa
    Pritchard, Colin C.
    Hampel, Heather
    Chassen, Alexis S.
    Simmons, Luke V.
    Schmidt, Amy P.
    Gao, Feng
    Brinton, Louise A.
    Backes, Floor
    Landrum, Lisa M.
    Geller, Melissa A.
    DiSilvestro, Paul A.
    Pearl, Michael L.
    Lele, Shashikant B.
    Powell, Matthew A.
    Zaino, Richard J.
    Mutch, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) : 4301 - +
  • [48] Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
    Tewari, Krishnansu S.
    Sill, Michael W.
    Coleman, Robert L.
    Aghajanian, Carol
    Mannel, Robert
    DiSilvestro, Paul A.
    Powell, Matthew
    Randall, Leslie M.
    Farley, John
    Rubin, Stephen C.
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 79 - 87
  • [49] Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
    Landen, Charles N.
    Buckanovich, Ronald J.
    Sill, Michael W.
    Mannel, Robert S.
    Walker, Joan L.
    Disilvestro, Paul A.
    Mathews, Cara A.
    Mutch, David G.
    Hernandez, Marcia L.
    Martin, Lainie P.
    Bishop, Erin
    Gill, Sarah E.
    Gordinier, Mary E.
    Burger, Robert A.
    Aghajanian, Carol
    Liu, Joyce F.
    Moore, Kathleen N.
    Bookman, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (21) : 2537 - 2545
  • [50] PHASE-II TRIAL OF ETOPOSIDE IN THE MANAGEMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    SLAYTON, RE
    BLESSING, JA
    DELGADO, G
    CANCER TREATMENT REPORTS, 1982, 66 (08): : 1669 - 1671
12345